Artwork

Content provided by The Podcast Studios. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Podcast Studios or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Breathwork: Asthma Biologic Therapies with Mr. Stephen Shelly (Part 2)

33:07
 
Share
 

Manage episode 485073383 series 3593326
Content provided by The Podcast Studios. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Podcast Studios or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Description

This week we speak to Mr Stephen Shelly again about the exciting but sometimes mysterious world of asthma biologics. We speak about the different biologics, going about getting approval to start an asthma biologic, training, and treatment response.

We speak about the potential impact that asthma biologics are going to have on the future of asthma (and hopefully COPD!), the cost benefit analysis and the limitations of these new wonder drugs.

Chapters

0.42min Intro to Biologics

1.00min Rapid fire round

1.52min Severe asthma & biologic eligibility

3.50min Available biologics

6.50min Which biologic?

7.30min Journey to asthma biologic

13.55min Asthma biologic administration

15.30min Monitoring while on asthma biologic

16.40min Training for asthma biologic admin at home

18.50min Assessing treatment response

21:10min Patient expectations

24:50min Are inhalers still needed?

26:12min Pitfalls in treatment with asthma biologics

28:54min Cost-benefit analysis

31.30min Take-home points

Show notes

Dupilumab https://www.nejm.org/doi/10.1056/NEJMoa1804092

Mepolizumab https://www.nejm.org/doi/10.1056/NEJMoa1403290

Omalizumab https://www.jacionline.org/article/S0091-6749(01)65945-1/fulltext

Benralizumab https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31322-8/abstractTezepelumab

https://doi.org/10.1164/rccm.202210-2005OC

Difficult to treat asthma (GINA) https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf

Asthma compliance programmes Ireland https://www.rcsi.com/dublin/research-and-innovation/innovation/investors-entrepreneurs-and-spin-outs/phyxiom

  continue reading

22 episodes

Artwork
iconShare
 
Manage episode 485073383 series 3593326
Content provided by The Podcast Studios. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Podcast Studios or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Description

This week we speak to Mr Stephen Shelly again about the exciting but sometimes mysterious world of asthma biologics. We speak about the different biologics, going about getting approval to start an asthma biologic, training, and treatment response.

We speak about the potential impact that asthma biologics are going to have on the future of asthma (and hopefully COPD!), the cost benefit analysis and the limitations of these new wonder drugs.

Chapters

0.42min Intro to Biologics

1.00min Rapid fire round

1.52min Severe asthma & biologic eligibility

3.50min Available biologics

6.50min Which biologic?

7.30min Journey to asthma biologic

13.55min Asthma biologic administration

15.30min Monitoring while on asthma biologic

16.40min Training for asthma biologic admin at home

18.50min Assessing treatment response

21:10min Patient expectations

24:50min Are inhalers still needed?

26:12min Pitfalls in treatment with asthma biologics

28:54min Cost-benefit analysis

31.30min Take-home points

Show notes

Dupilumab https://www.nejm.org/doi/10.1056/NEJMoa1804092

Mepolizumab https://www.nejm.org/doi/10.1056/NEJMoa1403290

Omalizumab https://www.jacionline.org/article/S0091-6749(01)65945-1/fulltext

Benralizumab https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31322-8/abstractTezepelumab

https://doi.org/10.1164/rccm.202210-2005OC

Difficult to treat asthma (GINA) https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf

Asthma compliance programmes Ireland https://www.rcsi.com/dublin/research-and-innovation/innovation/investors-entrepreneurs-and-spin-outs/phyxiom

  continue reading

22 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play